MARKET

CVKD

CVKD

Cadrenal Therape
NASDAQ
16.45
-0.05
-0.30%
After Hours: 16.00 -0.45 -2.74% 19:29 05/02 EDT
OPEN
16.80
PREV CLOSE
16.50
HIGH
17.00
LOW
16.29
VOLUME
27.88K
TURNOVER
--
52 WEEK HIGH
22.90
52 WEEK LOW
5.70
MARKET CAP
31.91M
P/E (TTM)
-1.8835
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at CVKD last week (0421-0425)?
Weekly Report · 5d ago
Weekly Report: what happened at CVKD last week (0414-0418)?
Weekly Report · 04/21 10:56
CADRENAL THERAPEUTICS INC - FILES PROSPECTUS SUPPLEMENT FOR $2.17 MLN ATM OFFERING - SEC FILING
Reuters · 04/17 10:12
Weekly Report: what happened at CVKD last week (0407-0411)?
Weekly Report · 04/14 10:47
Weekly Report: what happened at CVKD last week (0331-0404)?
Weekly Report · 04/07 10:47
Weekly Report: what happened at CVKD last week (0324-0328)?
Weekly Report · 03/31 10:56
Weekly Report: what happened at CVKD last week (0317-0321)?
Weekly Report · 03/24 10:47
Weekly Report: what happened at CVKD last week (0310-0314)?
Weekly Report · 03/17 10:55
More
About CVKD
More
Cadrenal Therapeutics, Inc. is a late-stage biopharmaceutical company focused on the development of tecarfarin, a new phase III-ready oral vitamin K antagonist anticoagulant to address unmet needs in anticoagulation therapy. Tecarfarin is a novel and reversible anticoagulant designed to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation. It is pursuing a product-in-a-pipeline approach with tecarfarin. Tecarfarin has orphan drug designation (ODD) for advanced heart failure patients with implanted mechanical circulatory support devices, including left ventricular assisted devices (LVADs). The Company also has ODD and fast-track status for tecarfarin in end-stage kidney disease and atrial fibrillation (ESKD+AFib). With tecarfarin, it is advancing a solution to address the unmet needs in anticoagulation therapy, aiming to reduce the clinical complexities of warfarin, a vitamin K antagonist.
Recently
Symbol
Price
%Change

Webull offers Cadrenal Therapeutics Inc stock information, including NASDAQ: CVKD real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CVKD stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading CVKD stock methods without spending real money on the virtual paper trading platform.